Arrowhead Pharma offers 'an attractive mix' of early and late-stage programs, analysts say
Arrowhead Pharma shares rose more than 5% Monday afternoon to $24.41 after Bank of America analysts initiated overage of the company with a Buy rating and...
Source: proactiveinvestors.com